130 related articles for article (PubMed ID: 37277283)
21. CCR2 and CCR5 genes polymorphisms in benign prostatic hyperplasia and prostate cancer.
Zambra FM; Biolchi V; Brum IS; Chies JA
Hum Immunol; 2013 Aug; 74(8):1003-8. PubMed ID: 23632061
[TBL] [Abstract][Full Text] [Related]
22. CYP1A1 and GSTM1 polymorphic genotypes in patients with prostate cancer in a Turkish population.
Aktas D; Hascicek M; Sozen S; Ozen H; Tuncbilek E
Cancer Genet Cytogenet; 2004 Oct; 154(1):81-5. PubMed ID: 15381379
[TBL] [Abstract][Full Text] [Related]
23. Free and total prostate specific antigen in benign prostate hyperplasia and prostate cancer.
Naz S; Ahmad S; Ghafoor F; Butt NS; Akhtar MW
J Coll Physicians Surg Pak; 2004 Feb; 14(2):69-71. PubMed ID: 15228865
[TBL] [Abstract][Full Text] [Related]
24. Genetic variants in 5p13.2 and 7q21.1 are associated with treatment for benign prostatic hyperplasia with the α-adrenergic receptor antagonist.
Qian X; Xu D; Liu H; Lin X; Yu Y; Kang J; Sheng X; Xu J; Zheng S; Xu D; Qi J
Aging Male; 2017 Dec; 20(4):250-256. PubMed ID: 28787260
[TBL] [Abstract][Full Text] [Related]
25. Contribution of genetic variation rs266882 to prostate-specific antigen levels in healthy controls with serum PSA below 2.0 ng/ml.
Song J; Park H; Lee G
Biochem Genet; 2013 Apr; 51(3-4):264-74. PubMed ID: 23315126
[TBL] [Abstract][Full Text] [Related]
26. Zinc and cadmium analysis in human prostate neoplasms.
Bryś M; Nawrocka AD; Miekoś E; Zydek C; Foksiński M; Barecki A; Krajewska WM
Biol Trace Elem Res; 1997; 59(1-3):145-52. PubMed ID: 9522056
[TBL] [Abstract][Full Text] [Related]
27. CA repeat polymorphism in the insulin-like growth factor-I gene is associated with increased risk of prostate cancer and benign prostatic hyperplasia.
Tsuchiya N; Wang L; Horikawa Y; Inoue T; Kakinuma H; Matsuura S; Sato K; Ogawa O; Kato T; Habuchi T
Int J Oncol; 2005 Jan; 26(1):225-31. PubMed ID: 15586244
[TBL] [Abstract][Full Text] [Related]
28. Insulin-like growth factor I (IGF-I) and IGF-binding protein-3 in benign prostatic hyperplasia and prostate cancer.
Khosravi J; Diamandi A; Mistry J; Scorilas A
J Clin Endocrinol Metab; 2001 Feb; 86(2):694-9. PubMed ID: 11158033
[TBL] [Abstract][Full Text] [Related]
29. Differentiation of benign prostatic hyperplasia and prostate cancer employing prostatic-specific antigen density.
Wolff JM; Scholz A; Boeckmann W; Jakse G
Eur Urol; 1994; 25(4):295-8; discussion 304. PubMed ID: 7519991
[TBL] [Abstract][Full Text] [Related]
30. Association of vitamin D receptor gene polymorphism with prostate cancer and benign prostatic hyperplasia in a Japanese population.
Habuchi T; Suzuki T; Sasaki R; Wang L; Sato K; Satoh S; Akao T; Tsuchiya N; Shimoda N; Wada Y; Koizumi A; Chihara J; Ogawa O; Kato T
Cancer Res; 2000 Jan; 60(2):305-8. PubMed ID: 10667581
[TBL] [Abstract][Full Text] [Related]
31. Prostate-specific antigen: insufficient discrimination between benign prostatic hyperplasia and organ-confined prostate cancer.
Wolff JM; Boeckmann W; Borchers H; Handt S; Reineke T; Jakse G
Urol Int; 1996; 57(3):170-4. PubMed ID: 8912446
[TBL] [Abstract][Full Text] [Related]
32. Significance of obesity markers and adipocytokines in high grade and high stage prostate cancer in North Indian men - a cross-sectional study.
Tewari R; Rajender S; Natu SM; Goel A; Dalela D; Goel MM; Tondon P
Cytokine; 2013 Aug; 63(2):130-4. PubMed ID: 23669251
[TBL] [Abstract][Full Text] [Related]
33. Apoptosis-related gene expression in benign prostatic hyperplasia and prostate carcinoma.
Iacopino F; Angelucci C; Lama G; Zelano G; La Torre G; D'Addessi A; Giovannini C; Bertaccini A; Macaluso MP; Martorana G; Sica G
Anticancer Res; 2006; 26(3A):1849-54. PubMed ID: 16827116
[TBL] [Abstract][Full Text] [Related]
34. Polymorphisms in the vitamin D receptor gene and the androgen receptor gene and the risk of benign prostatic hyperplasia.
Bousema JT; Bussemakers MJ; van Houwelingen KP; Debruyne FM; Verbeek AL; de La Rosette JJ; Kiemeney LA
Eur Urol; 2000 Feb; 37(2):234-8. PubMed ID: 10705205
[TBL] [Abstract][Full Text] [Related]
35. Polymorphic forms of prostate specific antigen and their interaction with androgen receptor trinucleotide repeats in prostate cancer.
Binnie MC; Alexander FE; Heald C; Habib FK
Prostate; 2005 Jun; 63(4):309-15. PubMed ID: 15599941
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of patients with diseases of the prostate using prostate-specific antigen density.
Wolff JM; Boeckmann W; Effert PJ; Handt S; Jakse G
Br J Urol; 1995 Jul; 76(1):41-6. PubMed ID: 7544203
[TBL] [Abstract][Full Text] [Related]
37. Increased risk of prostate cancer and benign prostatic hyperplasia associated with transforming growth factor-beta 1 gene polymorphism at codon10.
Li Z; Habuchi T; Tsuchiya N; Mitsumori K; Wang L; Ohyama C; Sato K; Kamoto T; Ogawa O; Kato T
Carcinogenesis; 2004 Feb; 25(2):237-40. PubMed ID: 14604900
[TBL] [Abstract][Full Text] [Related]
38. Association of IL10, IL10RA, and IL10RB polymorphisms with benign prostate hyperplasia in Korean population.
Yoo KH; Kim SK; Chung JH; Chang SG
J Korean Med Sci; 2011 May; 26(5):659-64. PubMed ID: 21532858
[TBL] [Abstract][Full Text] [Related]
39. Kallikarein-related peptidase 3 common genetic variant and the risk of prostate cancer.
Motamedi RK; Sarhangi N; Afshari M; Sattari M; Jamaldini SH; Samzadeh M; Mohsen Ziaei SA; Pourmand GR; Hasanzad M
J Cell Biochem; 2019 Sep; 120(9):14822-14830. PubMed ID: 31017705
[TBL] [Abstract][Full Text] [Related]
40. Polymorphisms of fibroblast growth factor receptor 4 have association with the development of prostate cancer and benign prostatic hyperplasia and the progression of prostate cancer in a Japanese population.
Ma Z; Tsuchiya N; Yuasa T; Inoue T; Kumazawa T; Narita S; Horikawa Y; Tsuruta H; Obara T; Saito M; Satoh S; Ogawa O; Habuchi T
Int J Cancer; 2008 Dec; 123(11):2574-9. PubMed ID: 18756523
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
